NASDAQ:BLUEbluebird bio Stock Price, Forecast & News

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BLUE shares have decreased by 1.1% and is now trading at $60.81. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for bluebird bio.

bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for bluebird bio.

bluebird bio Inc (NASDAQ:BLUE) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($3.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.05) by $0.41. The biotechnology company had revenue of $21.90 million for the quarter, compared to analysts' expectations of $8 million. bluebird bio had a negative net margin of 1,531.04% and a negative return on equity of 60.05%. bluebird bio's quarterly revenue was up 75.2% on a year-over-year basis. During the same period last year, the firm earned ($2.99) EPS. View bluebird bio's earnings history.

20 analysts have issued 12 month price targets for bluebird bio's stock. Their forecasts range from $70.00 to $195.00. On average, they expect bluebird bio's stock price to reach $115.47 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View analysts' price targets for bluebird bio.

Headlines about BLUE stock have been trending very negative on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. bluebird bio earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutbluebird bio.

Some companies that are related to bluebird bio include BioNTech (BNTX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA) and Ablynx (ABLYF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU) and Medivation (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (12.26%), Capital Research Global Investors (12.24%), Capital World Investors (7.80%), Sands Capital Management LLC (5.61%), BlackRock Inc. (5.18%) and Victory Capital Management Inc. (3.10%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View institutional ownership trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Wellington Management Group LLP, Capital International Investors, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, and William D Baird III. View insider buying and selling activity for bluebird bio.

BLUE stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, TimesSquare Capital Management LLC, Casdin Capital LLC, Two Sigma Investments LP, Fiera Capital Corp, Tarsadia Capital LLC, and Deutsche Bank AG. View insider buying and selling activity for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $60.81.

bluebird bio has a market capitalization of $3.38 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

The official website for bluebird bio is www.bluebirdbio.com.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]